Importantly, the use of single-agent BRAF inhibitors significantly elevated the risk of developing cSCC compared to dual BRAF/MEK inhibitors, with a substantial risk increase observed for both all-grade (RR 4.72, 95% CI: 2.42–9.20) and high-grade (RR 4.92, 95% CI: 2.64–9.16) cSCC in cancer patients [44]. The gene discussed is BRAF; the disease is skin squamous cell carcinoma.